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Abstract
Background: Patlak’s graphical analysis can provide tracer net influx constant (Ki) with limitation of assuming
irreversible tracer trapping, that is, release rate constant (kb) set to zero. We compared linear Patlak’s analysis to
non-linear three-compartment three-parameter kinetic model analysis (3P-KMA) providing Ki, kb, and fraction of free
18F-FDG in blood and interstitial volume (Vb).
Methods: Dynamic PET data of 21 lung cancer patients were retrospectively analyzed, yielding for each patient an
18F-FDG input function (IF) and a tissue time-activity curve. The former was fitted with a three-exponentially decreasing
function, and the latter was fitted with an analytical formula involving the fitted IF data (11 data points,
ranging 7.5–57.5 min post-injection). Bland-Altman analysis was used for Ki comparison between Patlak’s analysis and
3P-KMA. Additionally, a three-compartment five-parameter KMA (5P-KMA) was implemented for comparison with
Patlak’s analysis and 3P-KMA.
Results: We found that 3P-KMA Ki was significantly greater than Patlak’s Ki over the whole patient series, + 6.0% on
average, with limits of agreement of ± 17.1% (95% confidence). Excluding 8 out of 21 patients with kb > 0 deleted this
difference. A strong correlation was found between Ki ratio (=3P-KMA/Patlak) and kb (R = 0.801; P < 0.001). No significant
difference in Ki was found between 3P-KMA versus 5P-KMA, and between 5P-KMA versus Patlak’s analysis, with limits of
agreement of ± 23.0 and ± 31.7% (95% confidence), respectively.
Conclusions: Comparison between 3P-KMA and Patlak’s analysis significantly showed that the latter underestimates Ki
because it arbitrarily set kb to zero: the greater the kb value, the greater the Ki underestimation. This underestimation
was not revealed when comparing 5P-KMA and Patlak’s analysis. We suggest that further studies are warranted to
investigate the 3P-KMA efficiency in various tissues showing greater 18F-FDG trapping reversibility than lung cancer
lesions.
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Background
Positron emission tomography using [18F]fluorodeoxyglucose
(18F-FDG PET) imaging in oncology patients allows
physicians to quantify the increased glycolysis of cancer cells
[1]. In clinical routine, a tracer uptake index is easily available
and thus widely used, namely, the standardized uptake value
(SUV) [2, 3]. However, many factors can influence the
SUV outcome such as the uptake time, as reported
for example in lung tumors [4]. This is the reason
why, besides the SUV index, different quantitative pa-
rameters that may be obtained from kinetic model
analyses (KMAs) have been implemented in a number
of studies investigating various tissues [5–13]. These
kinetic parameters more accurately describe the tracer
trapping and may be useful to better characterize dif-
ferent tumor types or assess treatment response [14].
The KMAs both require a dynamic acquisition over
the tissue of interest to obtain its time-activity-curve
(TAC) and a serial blood sampling to estimate the so-
called input function (IF, i.e., 18F-FDG blood TAC).
Among these KMAs, Patlak’s analysis is usually consid-
ered as a gold standard that provides the 18F-FDG net in-
flux constant (i.e., the uptake rate constant, Ki) from a
linear fitting of graphical data [7]. However, it assumes an
irreversible tracer trapping, a well-identified drawback
since numerous studies have shown trapping reversibility
in various tissues, either under physiological or patho-
logical conditions [6, 9–11, 15].
Assuming that there may be a slow loss of the trapped
tracer to the blood, i.e., a reversible trapping, Patlak and
Blasberg derived a generalized non-linear equation in-
cluding a release rate constant (kb) in an exponential
term [8]. This non-linear equation may be addressed by
using an analytical approach, leading to a three-compart-
ment three-parameter KMA (3P-KMA). 3P-KMA has
been applied to healthy human lung and liver, allowing as-
sessment of both Ki (in mL min−1 mL−1), kb (in min
−1),
and fraction of free 18F-FDG in blood and interstitial vol-
ume (Vb; no unit; < 1; also called total blood volume dis-
tribution) [12, 15]. It relies on an analytical solution of
the non-linear Patlak’s equation that requires to use an IF
as a sum of exponentially decreasing functions and up to
three functions may usually describe the 18F-FDG IF
[16, 17]. Then, it leads to a non-linear formula that is
used to fit the experimental tissue TAC by simply adjust-
ing the three above-mentioned kinetic parameters, i.e.,
without any tissue TAC data transform.
To the best of our knowledge, comparison between
non-linear fitting by 3P-KMA and linear fitting by stand-
ard Patlak’s analysis that assumes an irreversible tracer
trapping has not been reported so far, whatever the tis-
sue either under physiological or pathological condi-
tions. Therefore, the primary aim of this study was to
make this comparison in a series of lung cancer patients
that was previously acquired [13]. Additionally, Ki, kb,
and Vb outcomes obtained from 3P-KMA were com-
pared to those obtained from a three-compartment five-
parameter KMA (5P-KMA) that is usually considered as
a reference model when tracer trapping is reversible.
Actually, 5P-KMA provides four kinetic (micro)para-
meters (and Vb) from which Ki and kb may be computed,
whereas the non-linear fitting of the 3P-KMA provides Ki
and kb without any additional computing.
Methods
Patients
Dynamic data of 21 patients (8 females, 13 males, 71 years
old on average, range 40–86) with non-small cell lung
cancer obtained from a previous prospective study were
retrospectively analyzed [13]. All patients who were en-
rolled in the prospective study provided written informed
consent before participating in it, and the further retro-
spective study received the approval of the ethics commit-
tees of our teaching hospitals. The patients’ mean weight
and height were 68 kg (range, 50–85) and 169 cm (range,
150–180), respectively. After 6 h of fasting before the
tracer injection, the preinjection average plasma glucose
concentration was 1.08 g L−1 (range, 0.87–1.28). The
lesion mean size was 31.8 mm (range, 14.7–52.2).
PET imaging and data processing
PET imaging procedure has been previously described in
details [13]. Briefly, a low dose CT scan was performed
(75 mA, 120 kV, pitch 0.938, rotation time 0.5 s) for at-
tenuation correction of PET emission data and for mor-
phologic information. Then, after an intravenous bolus
injection of 18F-FDG (mean 237 MBq; range, 134–507)
in a cannula previously inserted in the vein of the arm, a
3D thorax dynamic list-mode acquisition protocol was
started lasting 60 min (Gemini GXL, Philips Medical
System, Cleveland, USA; no respiratory gating). Images
were reconstructed using the iterative method RAMLA
LOR-3D, with a 144 × 144 matrix and pixel size of 4 ×
4 × 4 mm3. In particular, this dynamic acquisition pro-
vided 11 frames of 5 min each, leading to 11 data points
of the experimental 18F-FDG IF and of the experimental
cancer tissue TAC, ranging 7.5–57.5 min post-injection.
For determining the experimental 18F-FDG IF, in each
patient, a volume of interest (VOI) was drawn over the
descending thoracic aorta in each frame of the dynamic
acquisition yielding an intermediate 18F-FDG blood TAC
(i.e., intermediate IF). Then, the final IF was obtained
through a calibration of the intermediate IF with the
18F-FDG plasma value measured in a venous blood sam-
pling performed at 45 min post-injection, that is, when
an equilibrium is reached between 18F-FDG concentra-
tion in arterial and vein blood [3, 16]. VOIs for IF and
tissue TAC were semi-automatically placed over three
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consecutive slices to include the five hottest voxels
within the VOI.
Implementing Patlak’s analysis, 3P-KMA, and 5P-KMA
Assuming that there may be a slow loss of the trapped
tracer to the blood and when the analysis remains limited
to data collected for the period t > t* after injection, that
is, when the reversible compartments are in effective
steady state with the blood plasma, Patlak and Blasberg
derived a non-linear equation including a release rate
constant (kb) [8]:
AΤ tð Þ=Ap tð Þ ¼ Ki
Z t
o
Ap τð Þe‐Kb t‐τð Þdτ
 
= Ap tð Þ
 þ Vb
ð1Þ
AT(t) (in kBq mL
−1) is defined as the total tracer activ-
ity at time t per tissue volume unit that includes both
trapped tracer and free tracer in the blood and intersti-
tial volumes. Ap(t) (in kBq mL
−1) is the blood activity at
time t per blood volume unit, that is, the 18F-FDG IF.
In each patient, Patlak’s graphical analysis was imple-
mented from Eq. 1, setting kb = 0. Eleven cancer tissue
TAC data points and the corresponding 11 data points of
the experimental 18F-FDG IF, ranging 7.5–57.5 min post-
injection, were used. The lower limit of 7.5 min for this
range was chosen in order to limit the analysis to data col-
lected for the period t > t* after injection, as required by
Eq. 1 validity [7, 8]. Ki was determined as the slope of the
linear fitting of the Patlak’s plot showing AT(t)/Ap(t) ver-
sus the ratio of time integral of the right hand side of Eq.
1 to Ap(t), i.e., the so-called stretched time.
In each patient, 3P-KMA was implemented by first fit-
ting the 11 data points of the experimental 18F-FDG IF
with a three exponentially decreasing function derived
from Hunter’s results, after data were uncorrected for
the 18F physical decay. Hunter’s results were used, and
not Vriens’ ones as in previous studies, because the
former were established with blood sampling performed
at 55 min post-injection, in comparison with 25 min for
the latter [12, 15–17]:
Ap tð Þ ¼ A0  ½8:20 exp ‐9:3363 tð Þ þ 1:17 exp ‐α2  tð Þ
þ exp ‐α3  tð Þ
ð2Þ
In Eq. 2, the amplitude ratios of the three exponential
functions and the time constant of the first exponential
function (uncorrected for physical decay) were available
from Hunter’s results [16]. In each patient, A0 (leading
to virtual initial IF amplitude), α2, and α3 (time constants
of the second and third exponential functions, uncor-
rected for physical decay) were obtained by fitting the
experimental 18F-FDG IF data points (XLSTAT
Microsoft; Levenberg-Marquardt algorithm). Then, in
each patient, a formula was established by analytically
solving integral of Eq. 1 and by using the fitted three-
exponential IF of Eq. 2 involving kb [12, 15]:
AT tð Þ ¼ Ki A0  f8:20 ½ exp ‐9:3363 tð Þ‐ exp ‐ λþ kbð Þ  tð Þ=½ λþ kbð Þ‐9:3363
þ1:17 ½ exp ‐a2  tð Þ‐ expð‐ λþ kbð Þ  tÞ=½ λþ kbð Þ‐a2
þ½ exp ‐a3  tð Þ‐ exp ‐ λþ kbð Þ  tð Þ=½ λþ kbð Þ‐a3g
þVb  Ap tð Þ
ð3Þ
In Eq. 3, the 18F physical decay constant is λ, and Ki,
kb, and F were obtained in each patient by fitting the
18F-FDG tissue TAC (XLSTAT, Microsoft; Levenberg-
Marquardt algorithm), ranging 7.5–57.5 min post-
injection, uncorrected for 18F physical decay. Note that
previous studies used 18F-FDG tissue data obtained at
late dynamic PET imaging, i.e., beyond 2 h after injec-
tion, in comparison with the current ones obtained at
early imaging (7.5–57.5 min post-injection) [12, 15].
However, the rationale for deriving Eq. 3 remains identi-
cal, whatever the time of acquisition (>t* after injection).
In each patient, the 5P-KMA model was implemented
on PMOD software by using the whole experimental IF
and tissue TAC data points acquired from injection, with
very short frames including the bolus injection (version
3.0; PMOD Technologies, Switzerland) [13]. The 5P-KMA
model can provide four kinetic rate constants, i.e., K1, k2-3-
4 and Vb: K1 and k2 account for forward and reversed
transport between blood and reversible compartment, and
k3 and k4 account for forward and reversed transport be-
tween reversible and trapped compartment, respectively
[12, 15]. The rate constants Ki and kb may be computed
from K1, k2-3-4, as:
Ki ¼ K1 k3= k2 þ k3ð Þ ð4Þ
kb ¼ k2 k4= k2 þ k3ð Þ ð5Þ
Statistical analysis
A normal distribution of the α2 and α3 values (Eq. 2) in
the current study and in Hunter’s study could not be
clearly showed for each IF time constants; therefore, com-
parisons between the two studies were made by means of
non-parametric Mann-Whitney’s test (GraphPad Prism 6
software; two-tailed; 95% confidence level). Bland-Altman
analysis was used for Ki comparison between 3P-KMA
and Patlak’s analysis, as well as for further comparisons
between 3P-KMA and 5P-KMA, and between 5P-KMA
and Patlak’s analysis (GraphPad Prism 6 software; 95%
confidence level) [18].
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Results
Figure 1 shows an IF fitting in a typical patient. Values of
A0, α2, and α3 are presented for each patient in Table 1.
Range of IF fitting correlation coefficients over the patient
series was 0.989–0.999 (mean 0.996). The α2 and α3 values
found in the current study were significantly lower than
those of Hunter’s study (after removing the decay correc-
tion): P < 0.0001 for the two comparisons.
Figures 2 and 3 show linear Patlak’s fitting and non-linear
3P-KMA in the same patient as in Fig. 1. Values of Ki ob-
tained from Patlak’s analysis versus Ki, kb, and Vb obtained
from 3P-KMA are presented for each patient in Table 1.
The range of correlation coefficients for Patlak’s and
3P-KMA fitting over the patient series was 0.971–0.999
and 0.766–0.998 (mean 0.990 and 0.958), respectively. A
significant correlation was found between correlation
coefficients of IF fittings and those of 3P-KMA fittings (R =
0.631; P < 0.01; graph not shown).
3P-KMA Ki was found to be strongly correlated with
Patlak’s Ki (R = 0.995; P < 0.001; graph not shown). Figure 4
shows the comparison between 3P-KMA Ki and Patlak’s
Ki in the manner of Bland-Altman [18]. 3P-KMA Ki was
significantly greater than Patlak’s analysis Ki: Ki ratio (i.e.,
3P-KMA/Patlak) which was 1.060 ± 0.040 on average (95%
confidence limits), with 95% limits of agreement of 0.171.
When patients with kb > 0 were excluded (n = 8; Table 1),
3P-KMA Ki was no more significantly greater than
Patlak’s Ki: Ki ratio which was 1.014 ± 0.030 on average
(95% confidence limits), with 95% limits of agreement of
0.098. A strong correlation was found between Ki ratio
and kb (Fig. 5; R = 0.801; P < 0.001).
Values of Ki, kb, and Vb obtained from 3P-KMA and
values of K1, k2-3-4, Vb, Ki, and kb (computed from Eqs. 4
and 5) obtained from 5P-KMA are presented in Table 1.
Range of correlation coefficients for 5P-KMA fitting
over the patient series was 0.977–0.999 (mean: 0.989).
3P-KMA Ki was found to be strongly correlated with
5P-KMA Ki (R = 0.989; P < 0.001). No significant differ-
ence was found between 3P-KMA Ki and 5P-KMA Ki: Ki
ratio (i.e., 3P-KMA/5P-KMA) which was 1.017 ± 0.054 on
average (95% confidence limits), with 95% limits of agree-
ment of 0.230. No significant difference was found be-
tween 5P-KMA Ki and Patlak’s Ki: Ki ratio (Table 1) (i.e.,
5P-KMA/Patlak) which was 1.056 ± 0.074 on average (95%
confidence limits), with 95% limits of agreement of 0.317.
3P-KMA kb was found to be significantly correlated with
5P-KMA kb (R = 0.60; P < 0.01). No significant difference
was found between 3P-KMA kb and 5P-KMA kb: kb differ-
ence (i.e., 3P-KMA minus5P-KMA; kb ratio is not allowed
since division by zero is not allowed) which was 0.00041 ±
0.00083 min−1 on average (95% confidence limits), with
95% limits of agreement of 0.00359 min−1. No significant
correlation was found between 3P-KMA Vb and 5P-KMA
Vb (R = 0.12).
Figure 6 shows the tissue TAC and the part of trapped
tracer and of free tracer in blood and interstitial volume
(Eq. 3), by using mean values for IF and for 3P-KMA
parameters (Ki, kb, Vb) obtained over the current lung
cancer series.
Discussion
In each patient, 11 data points of the 18F-FDG IF were
fitted by using a three-exponential decreasing function.
These data points ranged 7.5–57.5 min post-injection,
that is, after an equilibrium has been reached between
compartments in order to satisfy the Patlak’s condition
t > t*. This function was derived from Hunter’s results,
of which A0, α2, and α3 were obtained by fitting (Eq. 2)
[16]. Indeed, the relative part of each exponential func-
tion to the IF area-under-curve (i.e., the total number of
molecules that are available to the tissues after injection)
is 1.14, 9.62, and 89.24% (by using the mean value of α1
by Hunter and of α2 and α3 reported in Table 1), re-
spectively. In other words, the part of the first exponen-
tial function in the whole IF, which mainly covers the IF
peak, is very limited, suggesting that the mean value of
α1 reported by Hunter may be used in each individual
[16]. Comparison between the fitted IFs of the current
study and those reported by Hunter et al. shows that the
former α2 and α3 values were significantly lower than the
latter ones (P < 0.0001) [16]. The IF fitting correlation co-
efficients were high (range, 0.989–0.999; P < 0.001; Fig. 1).
The major role of a reliable analytical IF as a sum of expo-
nential functions for implementing 3P-KMA (Eq. 3) is em-
phasized by the significant correlation between IF fitting
Fig. 1 Typical IF fitting (patient 9 in Table 1; R = 0.989; P < 0.001). PET
data (square) are uncorrected for 18F physical decay
Laffon et al. EJNMMI Research  (2018) 8:24 Page 4 of 8
Table 1 Fitting results in each patient for Patlak’s analysis, 3P-KMA and 5P-KMA (A0 in kBq mL
−1; α2, α3, k b k2-4 in min−1; Ki and K1 in
mL min−1 mL−1; Vb no unit)
Patient A0 α2 α3 Patlak’s
Ki
3P-KMA
Ki
3P-KMA
kb
3P-KMA
Vb
5P-KMA
K1
5P-KMA
k2
5P-KMA
k3
5P-KMA
k4
5P-KMA
Ki
5P-KMA
kb
5P-KMA
Vb
1 10.82 0.1210 0.0122 0.0329 0.0312 0.0000 0.08 0.0418 0.154 0.3615 0.0000 0.0293 0.0000 0.06
2 9.16 0.2283 0.0134 0.0308 0.0312 0.0000 0.07 0.0893 0.952 0.4250 0.0000 0.0276 0.0000 0.00
3 9.57 0.1442 0.0126 0.0806 0.0845 0.0008 0.20 0.1059 0.033 0.1401 0.0000 0.0859 0.0000 0.07
4 9.69 0.1470 0.0144 0.0376 0.0391 0.0000 0.22 0.1371 0.834 0.3091 0.0000 0.0371 0.0000 0.02
5 8.28 0.1069 0.0096 0.0192 0.0198 0.0000 0.18 0.0667 0.780 0.3351 0.0000 0.0201 0.0000 0.04
6 9.55 0.1288 0.0148 0.0366 0.0390 0.0000 0.13 0.1025 0.684 0.3083 0.0000 0.0319 0.0000 0.01
7 19.79 0.2130 0.0154 0.0471 0.0560 0.0012 0.16 0.1079 0.892 0.6850 0.0000 0.0469 0.0000 0.03
8 16.26 0.1580 0.0128 0.0368 0.0384 0.0000 0.07 0.0802 1.000 0.7798 0.0000 0.0351 0.0000 0.03
9 53.45 0.2245 0.0193 0.0403 0.0446 0.0018 0.03 0.1240 1.000 0.4740 0.0000 0.0399 0.0000 0.03
10 16.46 0.1527 0.0171 0.0352 0.0360 0.0000 0.25 0.1045 0.616 0.3115 0.0000 0.0351 0.0000 0.04
11 12.45 0.1347 0.0141 0.0363 0.0358 0.0000 0.12 0.1394 1.000 0.2935 0.0000 0.0316 0.0000 0.03
12 15.14 0.1579 0.0116 0.0157 0.0202 0.0056 0.28 0.0962 0.610 0.1871 0.0099 0.0226 0.0076 0.05
13 22.17 0.1345 0.0141 0.0222 0.0249 0.0026 0.33 0.1374 0.601 0.1434 0.0043 0.0265 0.0035 0.03
14 22.41 0.1137 0.0141 0.0124 0.0135 0.0000 0.28 0.1173 0.777 0.1269 0.0071 0.0165 0.0061 0.02
15 18.61 0.2594 0.0187 0.0165 0.0171 0.0000 0.23 0.0837 0.470 0.1501 0.0044 0.0202 0.0034 0.07
16 21.40 0.1317 0.0155 0.0384 0.0389 0.0000 0.07 0.0375 0.000 0.5850 0.9596 0.0375 0.0000 0.05
17 13.53 0.1472 0.0153 0.0297 0.0266 0.0000 0.04 0.0319 0.099 0.4346 0.0000 0.0260 0.0000 0.07
18 17.28 0.1964 0.0144 0.0273 0.0323 0.0046 0.09 0.1161 1.000 0.3852 0.0031 0.0323 0.0022 0.05
19 12.26 0.1636 0.0160 0.0305 0.0314 0.0011 0.25 0.1329 0.549 0.2267 0.0052 0.0388 0.0037 0.10
20 9.37 0.1075 0.0140 0.0647 0.0643 0.0000 0.22 0.1561 0.417 0.3546 0.0000 0.0717 0.0000 0.13
21 8.26 0.1353 0.0143 0.1310 0.1450 0.0002 0.10 0.1503 0.123 1.0000 0.0000 0.1338 0.0000 0.08
Mean 16.00 0.1574 0.0145 0.0391 0.0414 0.0009 0.16 0.1028 0.5995 0.3817 0.0473 0.0403 0.0013 0.05
SD 9.82 0.0426 0.0022 0.0263 0.0288 0.0016 0.09 0.0361 0.3454 0.2247 0.2091 0.0269 0.0023 0.03
Fig. 2 Patlak’s analysis performed in patient 9 (Table 1): y = 0.0403x
+ 0.0059 (R = 0.999; P < 0.001), indicating that the Ki of patient 9
is 0.0403 mL.min-1.mL-1
Fig. 3 Typical 3P-KMA fitting of 18F-FDG tissue TAC (patient 9 in
Table 1; R = 0.998; P < 0.001). PET data (square) are uncorrected for
18F physical decay
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correlation coefficients and those of 3P-KMA (R = 0.631;
P < 0.01). It is noteworthy that, although the current study
with 18F-FDG used a three-exponential decreasing func-
tion, 3P-KMA may also be efficient with either a mono-
or a bi-exponential IF depending on the tracer. Moreover,
the ways the exponentially decaying IF can be obtained
may be various: either from arterial or venous blood sam-
pling, or image-derived, or from population-based IF
models possibly scaled to later dynamic measurements on
blood pool ROIs [3, 19].
3P-KMA Ki was found to be 6.0% greater than Patlak’s
Ki, on average, with reasonable 95% limits of agreement
of 17.1%, according to Bland-Altman analysis (Fig. 4).
Moreover, when patients with kb > 0 were excluded, 3P-
KMA Ki was no more significantly greater than Patlak’s
Ki, with 95% limits of agreement of 9.8%. These findings
were in agreement with Patlak and Blasberg’s comment
suggesting that, in case of reversible trapping (kb > 0),
linear fitting of a concave curve rather than that of a
(true) linear one (kb = 0), results in an underestimation
of the slope and hence to Ki underestimation [8]. These
findings also suggest that 3P-KMA and Patlak’s analysis
may be used interchangeably to assess 18F-FDG uptake
in lung cancer lesions. However, the strong correlation
between Ki ratio (i.e., 3P-KMA/Patlak) and kb (and
hence, between Ki underestimation by Patlak’s analysis
and kb; Fig. 5) suggests that 3P-KMA may be more ap-
propriate than Patlak’s analysis to accurately assess Ki in
various 18F-FDG-positive cancer lesions, possibly
showing greater trapping reversibility than lung cancer
lesions [9–11].
No significant difference over the current series was
found between 3P-KMA Ki and 5P-KMA Ki and
between 3P-KMA kb and 5P-KMA kb. A further com-
parison strengthens the current findings, between the
current 3P-KMA outcomes and published ones by
Dimitrakopoulou-Strauss et al., who implemented
5P-KMA in nine patients with lung tumors: Ki = 0.0414
± 0.0288 min−1 (SD) and kb = 0.0009 ± 0.0016 min
−1 (SD)
Fig. 4 Ki ratio of 3P-KMA/Patlak against mean. Ki ratio was 1.060 ±
0.040 on average (central dashed line; 95% confidence limits not
shown), with 95% limits of agreement of 0.171 (upper and lower
dashed lines)
Fig. 5 Ki ratio of 3P-KMA/Patlak versus kb: y = 43.679x + 1.022,
R = 0.801; P < 0.001
Fig. 6 (Full) Average tissue TAC obtained from mean values of the
kinetic parameters (Ki, kb, Vb) found over current lung cancer series;
(dotted) trapped tracer TAC; (dashed) TAC of free tracer in blood
and interstitial volume. Peak time for tissue TAC and trapped tracer
TAC is 84 and 88 min, respectively. Data are uncorrected for 18F
physical decay
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for 3P-KMA (Table 1) versus the mean value of 0.0304
and 0.0009 min−1 for 5P-KMA by Dimitrakopoulou-
Strauss et al., respectively [11]. However, it should be em-
phasized that the measurement uncertainty of the 3P-KMA
outcomes may be expected to be lower than that of the
5P-KMA one because Ki and kb from 5P-KMA has to be
computed by using three independent kinetic (micro)para-
meters (Eqs. 4 and 5). As a result, the measurement uncer-
tainty of Ki and kb from 5P-KMA combines that of the
three (micro)parameters, whereas the measurement uncer-
tainty of Ki and kb from 3P-KMA may be obtained without
any further combination [20]. (Note that MU of 3P-KMA
outcomes was not available from XLSTAT that did not
allow a possible comparison with MU of 5P-KMA out-
comes.) The proposed line of argument may be associated
with Galli et al.’s results showing that close values of Ki
may be computed from different set of (micro)parameter
values [3]. It may also explain why, unlike for the compari-
son between 3P-KMA Ki and Patlak’s Ki, no significant dif-
ference was found between 5P-KMA Ki and Patlak’s Ki
and, hence, that the Ki underestimation by Patlak’s analysis
was not revealed by the latter comparison. It may also be il-
lustrated by the comparison of limits of agreement of 17.1
versus 31.7% that were found for the comparison between
3P-KMA and Patlak’s analysis versus the comparison
between 5P-KMA and Patlak’s analysis, respectively.
Furthermore, no significant correlation was found between
3P-KMA Vb and 5P-KMA Vb (R = 0.12), and the Vb mean
value over the current series was found to be 0.16 ± 0.09
(SD) and 0.05 ± 0.03 (SD), respectively (Table 1).
Consistently with the above-proposed comparison for Ki
and kb, comparison of the current 3P-KMA Vb value of
0.16 ± 0.09 (SD) with that of 0.17 ± 0.07 (SD) previously
published for 5P-KMA by Dimitrakopoulou-Strauss et al.
further strengthens the findings of the current study [11].
Unlike Patlak’s analysis, the 3P-KMA approach allows
expressing the whole tissue TAC as an analytical formula
(Eq. 3). Therefore, at each time point, it is possible to
compare it to that of its two components, that is, to the
trapped tracer TAC and to the free tracer TAC. This com-
parison is shown in Fig. 6 by using mean values for IF and
for 3P-KMA kinetic parameters that were obtained over
the current lung cancer series (Table 1). Furthermore, this
graph shows that the (mean) peak time for tissue TAC
and trapped tracer TAC is 84 and 88 min, which could
serve as landmarks to determine the optimal injection-
acquisition time delay in clinical practice.
A limitation of the study is that, although the current
3P-KMA results obtained for Ki, kb, and Vb were in agree-
ment with previous literature results by Dimitrakopoulou-
Strauss et al., the kb/Ki ratio was low, about 2% on average
in the current lung tumor series (Table 1) [11]. One could
argue that 3P-KMA has been previously applied at late
imaging to healthy liver that showed greater kb values than
those of lung tumors; however, we suggest that further
studies are warranted to investigate the 3P-KMA effi-
ciency in various tissues showing greater 18F-FDG trap-
ping reversibility than lung cancer lesions [9–11, 15].
Furthermore, we also suggest that future studies should
compare the performance of the 3P-KMA non-linear fit-
ting with that of a step-wise approach replotting non-linear
graphical data with different values of kb in order to recover
a linear fitting and hence to obtain Ki [8]. Finally, the
current study did not use respiratory gating and, in the case
of lesions in the lower lobes, respiratory artifacts may very
likely have affected outcomes of both 3P-KMA, Patlak’s
analysis, and 5P-KMA and thus might have had an influ-
ence on the reported SDs and limits of agreements.
Conclusions
Comparison between 3P-KMA and standard Patlak’s
analysis showed that the latter significantly underesti-
mates, on average, the net influx constant (Ki) value in
comparison with the former, because it arbitrarily set the
release rate constant (kb) to zero: the greater the kb
value, the greater the Ki underestimation. This under-
estimation was not revealed when comparing 5P-KMA
and Patlak’s analysis. We suggest that further studies are
warranted to investigate 3P-KMA efficiency in various
tissues, either physiological or pathological, showing
greater 18F-FDG trapping reversibility than lung cancer
lesions.
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